Zanzalintinib for recurrent or metastatic olfactory neuroblastoma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new pill, zanzalintinib, which may help slow or shrink tumors in people with a rare cancer called olfactory neuroblastoma that has come back or spread. The drug targets blood vessels that feed the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with olfactory neuroblastoma that has returned or spread.
- You have at least one tumor that can be measured on scans.
- You are well enough to be up and about (ECOG score 0 or 1).
- You have not been treated with a VEGFR inhibitor (a type of targeted therapy) before.
- Your blood counts, kidney function, and liver function are within certain limits.
- You are willing to use effective birth control during and for a period after the trial, if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called zanzalintinib for people with advanced or metastatic bone sarcomas that have not responded to standard treatments. It aims to see if the drug can help shrink or slow the growth of these tumors.
This trial is looking at whether a new combination of two drugs, zanzalintinib and pembrolizumab, can help people with certain types of advanced soft-tissue sarcoma that have not responded to other treatments. It aims to find out if the combination is safe and effective.
This trial tests the drug nivolumab for people with a rare nasal tumor (olfactory neuroblastoma) that has come back or spread and cannot be treated with surgery or radiation. You must have already tried chemotherapy and it stopped working. The goal is to see if nivolumab can shrink the tumor or slow its growth.
This trial tests a new drug, zanzalintinib, for people with adenoid cystic carcinoma that has come back or spread and can't be treated with local therapy. The drug may help slow or stop the cancer's growth.
This trial tests a drug called Zanzalintinib for people with meningioma that has come back or grown despite past treatments. It aims to see if the drug can stop or slow tumor growth.
This trial tests a new targeted therapy pill (XL092, also called zanzalintinib) for people with certain advanced sarcomas that have not responded to other treatments. The goal is to see if the drug shrinks tumors or slows their growth.
Hear when a new Metastatic Olfactory Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.